INTRODUCTION: INTERCEPT treatment is used to reduce platelet transfusion associated bacterial infections. Limited data are available in Switzerland. PATIENTS AND METHODS: Patients with thrombocytopenia or thrombocyte dysfunction requiring platelet transfusions were enrolled in a prospective cohort study on safety (primary endpoint) and efficacy (secondary endpoint) of INTERCEPT treated platelets (I-PLTs). I-PLTs were produced from double-dose apheresis products. Data on safety were actively recorded for each transfusion. RESULTS: A total of 551 I-PLT units (mean platelet dose: 2.6 ± 0.4 × 10(11)/unit) were transfused to 46 patients (mean number of platelet transfusions per patient: 12 ± 12.5). Fifty-one (9%) transfusions were associated with adverse events and 12 (2%) with acute transfusion reactions. Eleven serious adverse events were observed, none considered as related to the administration of I-PLT. Mean 1-4h and 16-24h CCIs were 10.1 ± 8.1 and 3.6 ± 6.6, respectively. CONCLUSION: The transfusion of I-PLT was associated with a good safety profile and adequate platelet count increments at 1-4h. Crown
INTRODUCTION: INTERCEPT treatment is used to reduce platelet transfusion associated bacterial infections. Limited data are available in Switzerland. PATIENTS AND METHODS: Patients with thrombocytopenia or thrombocyte dysfunction requiring platelet transfusions were enrolled in a prospective cohort study on safety (primary endpoint) and efficacy (secondary endpoint) of INTERCEPT treated platelets (I-PLTs). I-PLTs were produced from double-dose apheresis products. Data on safety were actively recorded for each transfusion. RESULTS: A total of 551 I-PLT units (mean platelet dose: 2.6 ± 0.4 × 10(11)/unit) were transfused to 46 patients (mean number of platelet transfusions per patient: 12 ± 12.5). Fifty-one (9%) transfusions were associated with adverse events and 12 (2%) with acute transfusion reactions. Eleven serious adverse events were observed, none considered as related to the administration of I-PLT. Mean 1-4h and 16-24h CCIs were 10.1 ± 8.1 and 3.6 ± 6.6, respectively. CONCLUSION: The transfusion of I-PLT was associated with a good safety profile and adequate platelet count increments at 1-4h. Crown
Authors: Gerda C Leitner; Markus Ho; Alexander Tolios; Georg Hopfinger; Werner Rabitsch; Philipp Wohlfarth Journal: Transfusion Date: 2020-04-22 Impact factor: 3.157
Authors: Laura Infanti; Andreas Holbro; Jakob Passweg; Daniel Bolliger; Dimitrios A Tsakiris; Ramona Merki; Alexandra Plattner; David Tappe; Johannes Irsch; Jin-Sying Lin; Laurence Corash; Richard J Benjamin; Andreas Buser Journal: Transfusion Date: 2019-10-01 Impact factor: 3.157
Authors: Simona Stivala; Sara Gobbato; Laura Infanti; Martin F Reiner; Nicole Bonetti; Sara C Meyer; Giovanni G Camici; Thomas F Lüscher; Andreas Buser; Jürg H Beer Journal: Haematologica Date: 2017-07-20 Impact factor: 9.941
Authors: Sara Castiglia; Katia Mareschi; Luciana Labanca; Graziella Lucania; Marco Leone; Fiorella Sanavio; Laura Castello; Deborah Rustichelli; Elena Signorino; Monica Gunetti; Massimiliano Bergallo; Anna Maria Bordiga; Ivana Ferrero; Franca Fagioli Journal: Cytotherapy Date: 2014-02-12 Impact factor: 5.414
Authors: Idrissa Diallo; Abderrahim Benmoussa; Jonathan Laugier; Abdimajid Osman; Walter E Hitzler; Patrick Provost Journal: Front Cardiovasc Med Date: 2020-03-19